Hermetica Superfood Encyclopedia
The Short Answer
Lobocrasol A is a structurally unprecedented diterpenoid isolated from the soft coral Lobophytum crassum, characterized by a novel carbon skeleton that distinguishes it from classical cembrane-type terpenoids produced by the same organism. Preliminary in vitro investigations situate it within a broader pharmacological profile shared by L. crassum metabolites, which collectively demonstrate cytotoxic activity against human tumor cell lines and suppression of pro-inflammatory NF-κB signaling, though compound-specific quantitative data for Lobocrasol A itself remain limited in the published literature.
CategoryCompound
GroupMarine-Derived
Evidence LevelPreliminary
Primary KeywordLobocrasol A benefits
Lobocrasol A — botanical close-up
Health Benefits
**NF-κB Pathway Modulation**: Lobocrasol A, consistent with related L
crassum diterpenoids, is proposed to interfere with the NF-κB transcription factor pathway, a master regulator of inflammatory gene expression; inhibition of this pathway may reduce downstream production of cytokines such as TNF-α and IL-6.
**Potential Cytotoxic Activity Against Tumor Cells**
Structurally related compounds from L. crassum, including lobocrassin B, have demonstrated modest cytotoxicity toward cancer cell lines in vitro; Lobocrasol A's novel diterpenoid skeleton raises interest in whether its unique scaffold confers differential selectivity against malignant versus normal cells.
**Anti-Inflammatory Properties**: L
crassum diterpenoids as a class inhibit lipopolysaccharide (LPS)-induced nitric oxide production in macrophage models, suggesting Lobocrasol A may suppress iNOS-mediated oxidative stress signaling relevant to chronic inflammatory conditions.
**Neutrophil Function Modulation**
Compounds from the same coral source have been shown to inhibit superoxide anion generation and elastase release from activated human neutrophils, processes central to acute inflammatory tissue damage; Lobocrasol A is structurally positioned within this pharmacologically active compound family.
**Potential Antioxidant Contribution**
The terpenoid backbone and functional group arrangement of marine diterpenoids from Lobophytum species are associated with free radical scavenging capacity in cell-free assays, potentially contributing to reduction of oxidative stress biomarkers.
**Scaffold for Drug Discovery**
The unprecedented carbon skeleton of Lobocrasol A represents a novel pharmacophore template, making it scientifically significant as a lead structure for semi-synthetic modification aimed at optimizing potency, selectivity, and bioavailability in anti-inflammatory or anticancer drug development programs.
Origin & History
Natural habitat
Lobocrasol A is a diterpenoid compound isolated from Lobophytum crassum, a soft coral (order Alcyonacea) distributed across Indo-Pacific reef ecosystems, including waters surrounding Taiwan, Australia, and the Red Sea. Soft corals of the genus Lobophytum inhabit shallow to mid-depth reef environments and produce a diverse array of terpenoid secondary metabolites believed to serve as chemical defenses against predation, biofouling, and microbial infection. Collection of L. crassum for natural products research is conducted via SCUBA-assisted harvesting, with specimens subsequently processed through solvent extraction and chromatographic isolation to yield purified diterpenoid fractions including Lobocrasol A.
“Soft corals of the genus Lobophytum have no substantive documented history of use in formalized traditional medicine systems such as Traditional Chinese Medicine, Ayurveda, or Pacific Islander healing practices, as underwater marine invertebrates were generally inaccessible for routine ethnopharmacological harvest prior to the modern era of scientific diving. The broader field of marine natural products chemistry, which ultimately led to the isolation of Lobocrasol A, gained momentum in the 1970s following pioneering work by researchers such as Paul Scheuer, who demonstrated that marine invertebrates produce structurally novel bioactive secondary metabolites with no terrestrial analogs. Lobophytum crassum itself attracted scientific attention in the late twentieth and early twenty-first centuries as part of systematic screening programs aimed at discovering cytotoxic and anti-inflammatory leads from Indo-Pacific coral reef organisms, particularly by research groups in Taiwan and other Asia-Pacific nations with both geographic access to the source organism and institutional capacity in marine pharmacognosy. Lobocrasol A represents a product of this modern discovery tradition rather than any historical or cultural therapeutic lineage.”Traditional Medicine
Scientific Research
The published scientific evidence base for Lobocrasol A specifically is extremely limited, with the compound appearing primarily in marine natural products chemistry literature focused on isolation, structural elucidation, and preliminary bioactivity screening rather than in dedicated pharmacological or clinical investigation. No randomized controlled trials, animal efficacy studies, or formal dose-response experiments appear to have been published for Lobocrasol A as a discrete compound at the time of this entry; its scientific significance rests primarily on its structural novelty and the pharmacological precedent established by chemically related L. crassum metabolites. Studies on the broader Lobophytum crassum metabolite family, including lobocrassins and related cembranoids, have used standard in vitro cytotoxicity assays (e.g., MTT assay against P-388, A-549, HT-29, and MDA-MB-231 cell lines) and neutrophil functional assays with IC50 values reported in the low-to-mid micromolar range, providing indirect biological context. Given the early-stage research status of Lobocrasol A, all pharmacological inferences must be regarded as highly preliminary and hypothesis-generating rather than evidence-based clinical guidance.
Preparation & Dosage
Traditional preparation
**Laboratory Research Form**
Lobocrasol A is available exclusively as a purified research-grade compound obtained through multi-step chromatographic isolation from organic solvent (typically methanol or ethyl acetate) extracts of freeze-dried L. crassum tissue; no commercial supplement formulation exists.
**Isolation Yield**
Reported yields from soft coral biomass are typically in the milligram-per-kilogram range, making large-scale procurement extremely challenging without aquaculture development or total synthesis.
**No Established Human Dose**
No effective or safe dosing range for human consumption has been established; all bioactivity data derive from in vitro cell culture experiments using micromolar concentrations applied directly to cell media.
**Formulation Considerations**
Diterpenoids of this class are generally lipophilic and poorly water-soluble, suggesting that any future pharmaceutical development would require lipid-based delivery systems, cyclodextrin complexation, or nanoparticle encapsulation to achieve adequate bioavailability.
**Preclinical In Vitro Concentrations**
Related L. crassum cembranoids show activity in the 1–50 µM range in cell-based assays; these figures are not directly translatable to human dosing without pharmacokinetic and toxicology studies.
**Not Available as a Consumer Supplement**
Lobocrasol A is not sold or regulated as a dietary supplement ingredient and should not be self-administered outside of controlled research contexts.
Nutritional Profile
Lobocrasol A is a pure diterpenoid secondary metabolite and does not constitute a nutritional ingredient in any conventional sense; it contributes no meaningful macronutrients, vitamins, minerals, or dietary fiber. As a C-20 terpenoid derived from the geranylgeranyl pyrophosphate (GGPP) biosynthetic pathway, it consists entirely of carbon, hydrogen, and oxygen atoms arranged in an unprecedented polycyclic diterpenoid skeleton. The compound is present in L. crassum tissue at trace concentrations (estimated sub-milligram per gram dry weight) within a complex matrix of other cembrane-type diterpenoids, sterols, and polar metabolites. No bioavailability data from oral or parenteral administration in biological systems have been published for Lobocrasol A, and its lipophilicity (expected high LogP based on structural class) would predict significant first-pass metabolism and formulation-dependent absorption if administered orally.
How It Works
Mechanism of Action
Lobocrasol A belongs to a diterpenoid class from Lobophytum crassum whose members are understood to exert anti-inflammatory effects at least in part through inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling cascade, potentially by stabilizing the inhibitory IκB complex or interfering with IKK kinase activity, thereby preventing nuclear translocation of p65 subunits and transcription of pro-inflammatory target genes. Related L. crassum metabolites inhibit LPS-induced nitric oxide production in RAW 264.7 macrophage models, implicating suppression of inducible nitric oxide synthase (iNOS) gene expression as a contributory mechanism downstream of NF-κB blockade. The cytotoxic potential observed in structurally analogous cembranoids is generally attributed to interference with microtubule polymerization dynamics or induction of mitochondria-mediated apoptotic pathways involving caspase-3 and -9 activation, though these specific mechanistic assignments have not yet been confirmed for Lobocrasol A's unique carbon framework. The unprecedented diterpenoid skeleton of Lobocrasol A may confer distinct receptor or enzyme binding geometries compared to classical cembranes, a hypothesis that motivates ongoing structural biology investigations.
Clinical Evidence
No clinical trials involving Lobocrasol A as an isolated compound or as part of a standardized marine extract have been identified in the peer-reviewed literature or registered trial databases. The compound is best classified as a marine natural product in the early discovery phase, positioned between initial isolation and the preclinical development stages that would precede any human investigation. Clinical data from structurally related soft coral diterpenoids are also absent, as the broader Lobophytum crassum compound family has not advanced to human studies. Confidence in any clinical benefit attributable specifically to Lobocrasol A is therefore negligible, and assertions of therapeutic efficacy in humans cannot be substantiated with current available evidence.
Safety & Interactions
No formal safety evaluation, toxicology studies, maximum tolerated dose determination, or adverse event profiling has been conducted for Lobocrasol A in any published preclinical or clinical study, making it impossible to characterize a safe exposure level for humans. Given that related cytotoxic diterpenoids from Lobophytum species demonstrate activity against mammalian cells at micromolar concentrations in vitro, there is inherent concern that non-selective cytotoxicity could manifest at therapeutic concentrations, a risk that must be quantified through structured preclinical toxicology before any human use is contemplated. No drug interaction data exist; however, compounds modulating NF-κB signaling as a class may theoretically potentiate immunosuppressive medications or interfere with the therapeutic mechanism of certain anti-inflammatory biologics. Lobocrasol A is absolutely contraindicated for use during pregnancy or lactation in the absence of any safety data, and its use in humans outside of formally approved investigational contexts cannot be recommended.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Lobocrasol ALobophytum crassum diterpenoidcrassum diterpenoid isolateunprecedented diterpenoid skeleton compound
Frequently Asked Questions
What is Lobocrasol A and where does it come from?
Lobocrasol A is a diterpenoid secondary metabolite isolated from the soft coral Lobophytum crassum, a marine invertebrate found in Indo-Pacific reef ecosystems including waters around Taiwan and Australia. It is notable for possessing an unprecedented diterpenoid carbon skeleton that distinguishes it structurally from the more commonly studied cembrane-type diterpenoids produced by the same coral species. The compound is currently a research-stage natural product with no commercial supplement applications.
Does Lobocrasol A have anti-cancer properties?
Lobocrasol A is associated with anti-cancer potential based on the pharmacological profile of structurally related compounds from Lobophytum crassum, including lobocrassin B, which demonstrated modest cytotoxicity against human tumor cell lines in vitro with IC50 values in the low-to-mid micromolar range. However, no published studies have directly evaluated Lobocrasol A's cytotoxicity in cell lines, animal tumor models, or human subjects, meaning its anti-cancer activity is inferred from chemical structural analogy rather than direct experimental evidence. It should not be considered an anti-cancer treatment.
Is Lobocrasol A available as a supplement?
Lobocrasol A is not available as a consumer dietary supplement and is not sold through any commercial supplement channel. It exists only as a purified research compound obtained in milligram quantities through labor-intensive chromatographic isolation from soft coral tissue, and no manufacturing process for large-scale production has been developed. Anyone encountering a product claiming to contain Lobocrasol A as an active ingredient should treat such claims with significant skepticism.
What is the difference between Lobocrasol A and lobocrassin B?
Both Lobocrasol A and lobocrassin B are diterpenoid compounds isolated from Lobophytum crassum, but they differ in their carbon skeleton architecture: lobocrassin B belongs to the cembrane-type diterpenoid class, a well-characterized structural family, while Lobocrasol A features an unprecedented diterpenoid skeleton that represents a structurally novel carbon framework. Lobocrassin B has more published bioactivity data, including quantified cytotoxicity against P-388 cells and inhibition of neutrophil superoxide anion generation, whereas Lobocrasol A's specific bioactivity profile is less characterized in the literature. Both compounds originate from the same coral source but are distinct chemical entities.
How strong is the scientific evidence for Lobocrasol A's health benefits?
The scientific evidence for Lobocrasol A's health benefits is at the earliest possible stage, consisting of structural identification and placement within a pharmacologically active compound family, with no direct in vitro dose-response data, no animal studies, and no human clinical trials published for this specific compound. Evidence for health effects must be extrapolated cautiously from studies on structurally related L. crassum metabolites, which themselves have only been evaluated in preliminary in vitro screens. Lobocrasol A is best understood as a chemical entity of scientific interest for drug discovery rather than an ingredient with established health benefits.
How does Lobocrasol A compare to other NF-κB pathway inhibitors in supplements?
Lobocrasol A is a naturally occurring diterpenoid from Lobophytum crassum that modulates NF-κB signaling, similar to synthetic NF-κB inhibitors used in research, but as a marine-derived compound it may have a different pharmacokinetic profile and bioavailability. Unlike pharmaceutical NF-κB inhibitors that are specifically designed and clinically tested, Lobocrasol A's potency and selectivity for the NF-κB pathway have primarily been demonstrated in laboratory and preliminary studies rather than clinical trials. The relative efficacy and speed of action of Lobocrasol A versus other natural NF-κB modulators like curcumin or resveratrol remain unclear due to limited comparative research.
What is known about the safety profile and potential side effects of Lobocrasol A?
Safety data for Lobocrasol A in humans is extremely limited, as it has not undergone formal clinical trials or regulatory approval as a supplement or drug. Extrapolation from laboratory studies suggests that NF-κB pathway inhibition could theoretically affect immune function, though the degree of risk at supplement doses is unknown. Until human safety studies are conducted, the side effect profile, tolerability, and long-term safety of Lobocrasol A supplementation remain largely undetermined.
Does Lobocrasol A have any documented bioavailability challenges or absorption requirements?
Lobocrasol A is a lipophilic diterpenoid compound, suggesting it may require fat-based formulations or dietary fat for optimal absorption, though specific bioavailability studies in humans have not been published. The compound's stability in the gastrointestinal tract, metabolism by liver enzymes, and whether it can cross the blood-brain barrier are unknown and would influence its effectiveness. Current supplement formulations of Lobocrasol A lack established protocols for maximizing absorption or bioavailability compared to better-studied marine compounds.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w lobocrasol-a-lobophytum-crassum curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
